# Adicet Bio, Inc. (ACET)

> Source: Nexqual · https://nexqual.com/ACET · data as of 2026-10-15 20:00 UTC · cite as "Nexqual, Adicet Bio, Inc. (ACET), nexqual.com/ACET" · informational, not investment advice.

**Price:** USD 5.14 (+5.11% on the day) · last close of Oct 15, 2026; US market closed, not a live price. Prev close 4.89 · day 4.88–5.17 · 52w 4.8–16.96 · market cap $48.1M · NCM

## Key facts
- Analysts: Buy (mean 2.00 on a 1–5 scale) (6 analysts), mean target USD 34.83 (range 18–90).
- Total return with dividends: 1Y -69.1% vs S&P 500 +18.1%; 5Y -96.0% vs S&P 500 +85.1%.
- Next earnings: 2026-11-05, EPS estimate USD -1.58, revenue estimate $0K.

## Analysts
Consensus Buy (mean 2.00 on a 1–5 scale), 6 analysts; mean target USD 34.83 (low 18, high 90).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-29 | Wedbush | Target raised | Outperform | $25 → $28 |
| 2026-09-28 | HC Wainwright & Co. | Target raised | Buy | $27 → $34 |
| 2026-09-18 | HC Wainwright & Co. | Reiterated | Buy | $27 |
| 2026-08-06 | Guggenheim | Target lowered | Buy | $100 → $90 |

## Total return (dividends reinvested)
|  | 1Y (from 2025-10-16) | 5Y (from 2021-10-11) |
|---|---|---|
| Total return | -69.1% | -96.0% |
| S&P 500 (SPY) | +18.1% | +85.1% |
| Per year | -69.2% | -47.4% |
| Volatility (annualized) | 78.4% | 90.1% |
| Max drawdown | -70.6% (Oct 2025→Oct 2026) | -98.5% (Nov 2022→Oct 2026) |

## Peers (Biotechnology)
RYTM (Rhythm Pharmaceuticals, Inc.) USD 87.97 +1.57% · BLTE (Belite Bio, Inc) USD 152.62 +0.49% · IOVA (Iovance Biotherapeutics, Inc.) USD 14.72 +1.52% · PRAX (Praxis Precision Medicines, Inc) USD 248.24 +2.01% · IONS (Ionis Pharmaceuticals, Inc.) USD 44.12 +4.11% · SYRE (Spyre Therapeutics, Inc.) USD 80.1 -0.44%

## More
Full page: https://nexqual.com/ACET · Free keyless MCP server with the same data and citations: https://mcp.nexqual.com/mcp · Guide for agents: https://nexqual.com/agents · https://nexqual.com/llms.txt